Developments with targeted enzymes in cancer therapy

Current Opinion in Immunology

Volumn 11, Issue 5, 1999, Pages 579-583

  Bagshawe, Kenneth D ^a   Sharma, Surinder K ^b   Burke, Philip J ^b   Melton, Roger G ^b   Knox, Richard J ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Enzacta Group PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTIBODY; ANTIMETABOLITE; CYTOTOXIC AGENT; ENZYME; MACROGOL DERIVATIVE; POLYMER; PRODRUG;

CANCER CHEMOTHERAPY; DRUG ACTIVATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENZYME THERAPY; HUMAN; IMMUNOGENICITY; NONHUMAN; REVIEW; SOLID TUMOR;

EID: 0032823192     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)00004-7     Document Type: Review

References (46)

1. Moolten FL, Cooperbrand SR Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science. 169:1970;68-70.
2. Vitetta E, Krolick K, Miyama-Inaba K, Cushley W, Uhr J Immunotoxins. A new approach to cancer therapy. Science. 219:1983;644-650.
3. Bagshawe KD Antibody directed enzymes revive anti-cancer prodrug concept. Br J Cancer. 56:1987;531-532.
4. Senter PD, Saulnier MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellstrom I, Hellstrom KE Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA. 85:1988;4842-4846.
5. Bagshawe KD Towards generating cytotoxic agents at cancer sites. Br J Cancer. 60:1989;275-289.
6. Sharma SK Accelerated clearance systems. Adv Drug Deliv Rev. 22:1996;315-324.
7. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P Antibody directed enzyme prodrug therapy (ADEPT): a pilot scale clinical trial. Tumor Targeting. 1:1995;17-29.
8. Eccles SA, Springer CJ, Boxer GA, Dean CJ, Melton RG, Springer CJ Antibody directed enzyme prodrug therapy causes regression of established breast carcinoma xenografts. Brit J Cancer. 69(suppl xxi):1994;15.
9. Martin J, Stribbling SM, Poon GK, Begent RHJ, Napier M, Sharma SK, Springer CJ Antibody directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol. 40:1997;189-201.
10. Bagshawe KD, Sharma SK Cyclosporin delays host immune response to antibody enzyme conjugate in ADEPT. Transplant Proc. 28:1996;3156-3158.
11. Ledermann JA, Begent RHJ, Bagshawe KD Cyclosporin A prevents the anti murine antibody response to a monoclonal antibody in rabbits. Br J Cancer. 58:1988;562-566.
12. Bagshawe KD, Napier M Early clinical studies with ADEPT. Melton RG, Knox RJ Enzyme-Prodrug Strategies for Cancer Therapy. 1999;199-207 Kluwer Academic, London.
13. Blakey DC, Davies DH, Dowell RI, East SJ, Burke PJ, Sharma SK, Springer CJ, Mauger AB, Melton RG Anti-tumor effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Br J Cancer. 72:1995;1083-1088.
14. Seymour LW Passive tumor targeting of soluble macromolecule and drug conjugates. Crit Rev Ther Drug Carr Syst. 9:1992;135-187.
15. Matsumura Y, Maeda H A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor mechanism. Cancer Res. 46:1986;6387-6392.
16. Bagshawe KD, Burke PJ, Knox RJ, Melton RG, Sharma SK Targeting enzymes to cancers - new developments. Exp Opin Invest Drugs. 8:1999;161-172. A general review of recent developments in targeting enzymes to tumours (77 references).
17. Abuchowski A, David FF, Davis S Immunosuppressive properties and circulating life of achromobacter Glutaminas-Asparaginase covalently attached to polyethylene glycol in man. Cancer Treat Rep. 65:1981;1077-1081.
18. Nucci ML, Shorr R, Abuchowski A The therapeutic value of polyethylene glycol-modified proteins. Adv Drug Deliv Rev. 6:1991;133-151.
19. •] are detailed reviews of enzymes and prodrugs, including conjugation and phage technology.
20. •].
21. Schmitz JC, Grindey GB, Schultz RM, Priest DG Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Biochem Pharmacol. 48:1994;319-325.
22. Jackman A, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR ICI D1694, a quinazoline antifolate thymidylate synthetase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo; a new agent for clinical study. Cancer Res. 51:1991;5579-5586.
23. Wolfe LA, Millin RJ, Laethem R, Blumenkopf TA, Cory M, Miller JF, Keith BR, Humphreys J, Smith GK Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1; in vitro and in vivo studies with prodrugs of methotrexate and thymidylate synthetase inhibitors GW1031 and GW1843. Bioconj Chem. 10:1999;38-45. An account of a study aimed at using a modified human enzyme to activate specific prodrugs.
24. Beardsley GP, Moroson BA, Taylor EC, Moran RG A new folate antimetabolite 5,10 dideaza-5, 6,7,8 tetra hydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem. 264:1989;328-333.
25. Wallace PM, Senter PD In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard conjugates. Bioconj Chem. 2:1991;349-352.
26. Senter PD Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J. 4:1990;188-193.
27. Senter PD, Hirschberg DL, Ashe SA, Hellstrom KE, Hellstrom I Enhancement of the in vitro and in vivo activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res. 49:1989;5789-5792.
28. Smal MA, Dong Z, Cheung HT, Asano Y, Escoffier L, Costello M, Tattersall MH Activation and cytotoxicity of 2-α-aminocyl prodrugs of methotrexate. Biochem Pharmacol. 49:1995;567-574.
29. Smith GK, Banks S, Blumenkopf TA, Cory M, Humphreys J, Laethem RM, Miller J, Moxham CP, Mullin R, Ray PHet al. Toward antibody directed enzyme prodrug therapy with the T268G mutant of human carboxy-peptidase A1 and novel in vivo stable prodrugs of methotrexate. J Biol Chem. 272:1997;15804-15816.
30. Wallace PM, MacMaster JF, Smith VF, Kerr DE, Senter PD, Cosand WL Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res. 54:1994;2719-2723.
31. Adrianomenjamahary S, Dong X, Florent JC, Gandel G, Gesson JP, Jacquesy JC, Koch M, Michel S, Mondon M Synthesis of novel targeted prodrugs of anthacyclines potentially activated by a monoclonal antibody galactosidase conjugate. Bioorg Medicinal Chem Lett. 2:1992;1093-1096.
32. Rowlinson-Busza G, Epenetos AA Targeted delivery of biological and other antineoplastic agents. Curr Opin Oncol. 4:1992;1142-1148.
33. Roffler SR, Wang SM, Chern JW, Yeh MY, Tung E Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol. 42:1994;2062-2065.
34. Haisma HJ, van-Muijen M, Pinedo HM, Boven E Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-glucuronide conjugate in the specific treatment of cancer. Cell Biophys. 25:1994;185-192.
35. Meyer DL, Law KL, Payne JK, Milcolajzyk SD, Zarrinmayeh H, Jungheim LN, Kling J, Shepherd TA, Starling JJ Site specific prodrug activation by antibody-lactamase conjugates. Bioconj Chem. 6:1995;440-446.
36. Alexander RP, Beeley NRA, O'Driscoll M, O'Neill FP, Millican TA, Pratt AJ, Willenbrock FW Cephalosporin nitrogen mustard carbamate prodrugs for 'ADEPT'. Tetrahedron Lett. 32:1991;3269-3272.
37. Vrudhala VM, Svensson HP, Senter PD Cephalosporin derivatives of doxorubicin and melphalan and their activation by monoclonal antibody-lactamase conjugates. J Med Chem. 38:1995;1380-1385.
38. Knox RJ, Friedloss F, Boland MP The bioactivation of CB1954 and its use as a prodrug in antibody directed enzyme prodrug therapy (ADEPT). Cancer Metastatis Rev. 12:1993;195-212.
39. Friedlos F, Denny WA, Palmer BD, Springer CJ Mustard prodrugs for activation by Escherichia coli nitroreductase in gene directed enzyme prodrug therapy. J Med Chem. 40:1997;1270-1275.
40. Mauger DL, Burke PJ, Somami HH, Friedlos F, Knox RJ Self-immolative prodrugs. Candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J Med Chem. 37:1994;3452-3458.
41. Bignami GS, Senter PD, Grothaus PG, Fischer KJ, Humphreys T, Wallace PM N-(4′-hydroxyphenylacetyl) palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody peniciilin G amidase conjugate. Cancer Res. 52:1992;5759-5764.
42. Vrudhala VM, Senter PD, Fischer KJ, Wallace PM Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate. J Med Chem. 36:1993;919-923.
43. Blakey DC, Boyle FT, Davies DH, Dowell RL, Heaton DW, Rose MS, Slater AM, Eggelte HJ, Tarragpma-Fiol A, Taylorson CJ Mutant human ribonuclease for use in antibody directed enzyme prodrug therapy (ADEPT). Br J Cancer. 75(suppl 1):1997;36.
44. Lin JT, Bertino JR Update on Trimetrexate, a folate antagonist with anti-neoplastic and antiprotozoal properties. Cancer Invest. 9:1991;159-172.
45. Jackman AJ, Kelland LR, Kimbell R, Brown M, Gibson W, Aherne GW, Hardcastle A, Boyle FT Mechanisms of acquired resistance to the quinazoline thymidylate synthetase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer. 71:1995;914-924.
46. Boritzki TJ, Barlett CA, Zhang C, Howland EF, Margosiak SA, Palmer CL, Romines WH, Jackson RC AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drug. 14:1996;295-303.